ranQ
ranQ
ranQ
DirectoryIndustriesPlacesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The leading AI company directory, built to boost AI visibility.

DEENFRIT
Product
  • Pricing
  • Directory
  • Industries
  • Trust Score
Company
  • About
  • Partner program
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint745,937 companies indexed · Last updated: today
DirectoryIndustryPharmaceutical IndustryAllschwilNeurocrine Switzerland GmbH
Neurocrine Switzerland GmbH Logo
Verified· 2 sourcesTrust Score
Summary

About the company

Neurocrine Switzerland GmbH conducts research and development of treatments for neurological, neuroendocrine and neuropsychiatric disorders. The organisation’s portfolio includes approved medicines for conditions such as tardive dyskinesia, chorea associated with Huntington’s disease, congenital adrenal hyperplasia, endometriosis and uterine fibroids, and it maintains a pipeline with compounds in mid‑to‑late stage clinical development.

AI-generated
Offering

Products & services

Industry:Pharmaceutical Industry
LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
4.1/5

Neurocrine Switzerland GmbH

✓ Offered5
Medicines
Medicines for neurological, psychiatric, and endocrine disorders, including approved therapies for tardive dyskinesia, Huntington’s chorea, classic congenital adrenal hyperplasia, and hyperphagia in Prader-Willi syndrome.
Research and Development of Drug Candidates
Research and development programs in neurology, endocrinology, psychiatry, and immunology, spanning preclinical to late clinical phases for small molecules, peptides, antibodies, and gene therapy.
Clinical Trials
Clinical trials in neurology, endocrinology, and psychiatry to evaluate investigational treatments, including studies in epilepsy, schizophrenia, major depressive disorder, CAH, and obesity.
Therapeutic Focus Areas
Therapeutic areas with information on diseases and treatment areas in neurology, endocrinology, and psychiatry, including TD, Huntington’s chorea, CAH, epilepsy, and Alzheimer’s-related symptoms.
Funding & Support Requests Portal
Portal for funding and support requests related to Neurocrine Biosciences, accessible via the company navigation.
Trust & reputation

ranQ Trust Score of Neurocrine Switzerland GmbH: 4.1 out of 5.0

Trust Score4.1/ 5.0

High

x

Data basis 54% · As of October 2026

Neurocrine Switzerland GmbH has no value in the Reputation area of the ranQ Trust Score because no data is available. The area carries 42% of the weighting and drops out of the calculation for this profile; it does not lower the score, only the reported data basis.
x
CriterionValueWeight
  • Review quality: No data point — the criterion is taken out of the weighting and does not lower the score.—24%
  • Review volume: No data point — the criterion is taken out of the weighting and does not lower the score.—10%
  • Review recency: No data point — the criterion is taken out of the weighting and does not lower the score.—8%
Neurocrine Switzerland GmbH scores 61.5 out of 100 points in the Substance area of the ranQ Trust Score. This area carries 28% of the weighting.
x
CriterionValueWeight
  • Establishment: Years since founding or brand launch, logarithmic. The maximum is reached at 15 years.50.012%
  • Company size: The headcount band, researched by ranQ or stated by the company. It is scored in steps rather than by head count, because the data only provides bands.55.07%
Neurocrine Switzerland GmbH scores 83.3 out of 100 points in the Identity area of the ranQ Trust Score. This area carries 22% of the weighting.
x
CriterionValueWeight
  • Verification: Official register entry (commercial register with UID or professional-body record, 55 points), confirmed domain (20 points) and confirmed ranQ profile (up to 25 points, depending on completeness).83.322%
Neurocrine Switzerland GmbH scores 100.0 out of 100 points in the Visibility area of the ranQ Trust Score. This area carries 8% of the weighting.
x
CriterionValueWeight
  • Website authority: Ahrefs' Domain Rating measures, on a scale of 0 to 100, how strongly a website is linked from other websites. For Swiss SMEs the range up to 40 is typical; the maximum is reached at 35.100.04%
  • Media authority: No data point — the criterion is taken out of the weighting and does not lower the score.—4%
Qualifications+0.00

Neurocrine Switzerland GmbH reaches a ranQ Trust Score of 4.1 out of 5.0 — rated «High». No public customer reviews are available for this provider; the rating is based on the remaining criteria. The data basis is 54%, so the score is backed by part of the criteria. As of October 2026.

The Trust Score cannot be bought and is calculated from publicly verifiable data.

Knowledge

No knowledge articles yet

Once Neurocrine Switzerland GmbH has claimed this profile, we'll publish editorial articles and case studies here together.

Get started
Comparisons

Neurocrine Switzerland GmbH in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank Neurocrine Switzerland GmbH by reviews, experience and specialisations.

Is this your company?

Claim the company profile of Neurocrine Switzerland GmbH to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Hegenheimermattweg 167a
4123 Allschwil

At a glance

Legal form
Limited Liability Company
UID
CHE-288.406.862
Founded
2023 · 3 years
Last commercial register change
September 8, 2026
Employees
1 to 10
Legal form: Graded by liability and disclosure. The weight is kept small: a sole proprietorship is not a dubious company, it is just liable differently.
88.0
6%
  • Branch offices: Branch offices linked in the commercial register. Having none is normal and costs no points.70.03%
    • Full methodology

    Similar companies

    MG
    MiHKAL GmbH
    Allschwil
    AP
    Actelion Pharmaceuticals Ltd
    Allschwil
    BP
    Basilea Pharmaceutica AG, Allschwil
    Allschwil
    CT
    CAPTOR THERAPEUTICS GmbH
    Allschwil
    AT
    Alloy Therapeutics (Switzerland) AG
    Allschwil
    IP
    Idorsia Pharmaceuticals Ltd
    Allschwil
    GG
    Gubra GmbH
    Allschwil
    TP
    T3 Pharmaceuticals AG
    Allschwil